FREE WHITE PAPER
Regulatory Strategy: From Priorities to a Robust Roadmap in 6 Steps
A Practical Guide for Executive Management and Heads of Regulatory Affairs: identify critical paths, clarify dependencies, and support decision-making.
Strategy & Market Access: MDR · IVDR · International
Strategic Consulting for Medical Device and IVD Manufacturers
Strategic guidance instead of surprises: Metecon categorizes requirements, risks, and dependencies, identifies critical paths, and provides the foundation for informed decisions—as a strategic partner that also delivers results.
15+ years of RA strategy consulting · 120+ gap assessments · 25+ C-level workshops15+
Years of RA Strategy Consulting
250+
Gap Assessments Conducted
25+
Facilitated C-Level Workshops
25+
Years of Focus on MedTech
Overview
Strategy & Management
Market Access & Scaling
When Strategic Consulting Makes a Difference
For medical devices, compliance with regulatory requirements determines whether a product can be sold—and accounts for a large portion of the development effort. Difficulties rarely arise from individual requirements, but rather where priorities, dependencies, and decisions intersect.
Here’s how Metecon supports you: We organize requirements, risks, and dependencies and provide scenarios for a planned, manageable approach. We help you identify critical paths and provide clarity for informed decisions. During implementation, we ensure that Regulatory Affairs, Quality Management, Clinical Affairs, and Development work together effectively so that goals can be achieved in a planned and predictable manner.
"Strategic management instead of surprises: We highlight the regulatory implications of operational projects and provide the basis for informed decisions."
Dr. Julia Bubeck · Head of Operations · Metecon GmbH
Three Problems That Strategic Consulting Solves
Robust Prioritization
Without clear prioritization, resources are spread across many areas—but not the critical ones. We make the truly crucial tasks visible and manageable.
Interfaces Without Rework
Friction between RA, QM, Clinical Affairs, and R&D leads to rework and inconsistent documentation. We align all functions with the same priorities.
Controllable Marketability
Sales and delivery capacity are essential assets, but they are often neither evaluated nor managed. We turn them into a predictable component of your strategy.
Strategy and Implementation from a Single Source
Many consultants offer advice without truly understanding the big picture. Metecon is both: a strategic sparring partner and an implementation partner throughout the entire product life cycle—from quality management to technical documentation, clinical and regulatory affairs, and post-market activities. The added value typically begins in the design and development phase or when making portfolio decisions—and wherever changes, growth, or increasing regulatory complexity arise.
Strategic Management: Priorities, Critical Paths, Decisions
We work with you to develop a regulatory strategy that aligns operational initiatives with their implications: Which requirements can be met and when, which dependencies exist, and which path leads to the goal with the least risk? This transforms a list of tasks into a well-reasoned sequence with clear decisions.
Marketing Authorization and Regulatory Strategy (MDR/IVDR/International)
We develop the regulatory strategy based on the intended purpose, classification, and target markets—for medical devices (MDR), in-vitro diagnostic medical devices (IVDR), and international procedures. This results in a robust roadmap with milestones, documentation requirements, and decision points.
Aligning QM, Development, RA, and Clinical Affairs on Shared Priorities
Regulatory priorities are derived centrally once and made visible to all functions. This prevents rework, ensures consistency in claims, IFUs, labeling, and supporting documentation, and ensures that all stakeholders contribute to the same decision-making logic.
Strategy Workshop: Process & Outcomes
-
Clarify the Starting Point and Objectives – products, markets, pressure to make a decision
-
Gap Assessment: identifying requirements, risks, and dependencies
-
Identify Critical Paths and Scenarios
-
Prioritized Roadmap with Milestones and Responsibilities
- Concrete next steps—if desired, we’ll move directly to implementation
Strategically Managing Changes & Audit Readiness
Product changes, new suppliers, updates to standards, or organizational decisions have regulatory implications that often only become apparent after some delay. We assess planned changes in advance for their regulatory implications (change impact), define what constitutes a significant change, and ensure that certificates, technical documentation, and supply capability remain consistent. This ensures you are always prepared to provide meaningful responses during audits by the Notified Body and regulatory authorities—making inspection and audit readiness an integral part of your strategy.
Typical Reasons for Making a Decision
- Portfolio decisions and product changes
- Entry into new markets or new product categories
- Growth, reorganization, or building in-house RA capacity (build vs. buy)
- Increasing regulatory complexity (e.g., MDR/IVDR transition, EU AI Act)
Strategically Managing Market Access, Portfolio, and Scaling
Market access is more than just registration or approval: It involves target-market-specific requirements, the right market follow-up, and structures that grow with the company. We integrate regulatory strategy with operational implementation throughout the entire life cycle.
Areas of Expertise in Strategic Consulting
Market Access & Internationalization
Identifying target market-specific requirements (EU and international), defining market implications and dependencies, and managing them consistently.
Gap Assessment & Roadmap
Assessing gaps between current status and regulatory requirements and translating them into a prioritized, robust roadmap.
Portfolio & Life Cycle Strategy
Evaluating and managing "build vs. buy" decisions, product changes, and portfolio decisions based on regulatory considerations.
Digitalization of Regulatory Processes
Building processes, responsibilities, and data structures that are effective, efficient, and scalable over the long term.
QMS & Marketability
Designing processes to ensure that certifications and delivery capabilities are maintained and that they pass audits.
Regulatory Resilience
Establishing structures that allow us to manage changes and new market demands in a predictable manner—rather than being caught off guard by them.
U.S. Market Access: FDA Strategy (510(k), PMA, De Novo)
The U.S. market operates according to its own logic. We work with you to determine the appropriate FDA pathway and the most efficient sequence for EU approval, so that clinical and technical evidence can be reused rather than having to be provided twice.
-
Regulatory Pathway: 510 (k) (Substantial Equivalence), De Novo (new, lower-risk product classes), or PMA (high-risk)
-
Pre-Submission (Q-Sub): Early coordination of the testing strategy and evidence with the FDA
-
Classification: 513(g) inquiry in cases of unclear product classification
-
QMSR Transition: Alignment of 21 CFR 820 with ISO 13485—a single QM system for the EU and the U.S.
-
U.S. Agent: Consider and appoint this mandatory role for foreign manufacturers early on
EU Authorised Representative & Clarity on Roles: Manufacturer, EU-REP/EC-REP, Importer, Distributor
Market access can be hindered by unclear roles. We clarify the obligations along the supply chain—manufacturer, European Authorised Representative (EU-REP/EC-REP), importer, and distributor—and ensure that responsibilities, contracts, and labeling (PRRC, UDI, labeling) align. Metecon’s Representative Services also allow you to directly fulfill the role of Authorised Representative.
Dr. Julia Bubeck
Head of Operations · Metecon GmbHAt Metecon, Dr. Julia Bubeck is responsible for the operational management of complex strategy and implementation projects. With over 15 years of experience in regulatory strategy consulting, she bridges the gap between executive leadership and the realities of regulatory affairs, quality management, clinical affairs, and development—ensuring that strategy translates into actionable results. Do you have questions about your own regulatory strategy? If so, please don't hesitate to contact Julia.
"We help you identify the regulatory implications of your decisions early on—so you can take the initiative rather than just react."
– Dr. Julia Bubeck, Head of Operations, Metecon
Frequently Asked Questions About Strategic Consulting
Strategic practical issues related to prioritization, management, and market access.
Which benefits can external support provide in developing a regulatory strategy?
External strategy consulting brings objectivity, experience from numerous projects, and a neutral approach to prioritization. Metecon assesses requirements, risks, and dependencies, identifies critical paths, and lays the groundwork for informed decisions—ensuring that resources are allocated to the truly critical tasks.
How can we ensure that RA, QM, Clinical Affairs, and Development are all working based on the same priorities?
By centrally defining regulatory priorities and making them visible to all functions, Metecon aligns RA, QM, Clinical Affairs, and Development with the same decision-making logic, thereby avoiding rework and inconsistent documentation.
How can you tell if your regulatory planning is sound?
Robust planning remains effective even in the face of changes, growth, and new market demands. Warning signs include constant reprioritization, surprises during audits, and unclear dependencies. Metecon reviews the planning through a gap assessment and identifies weaknesses early on.
Which regulatory considerations should be clarified before making portfolio decisions or entering a market?
Before making such decisions, it is important to clarify classification, certification requirements, certification and delivery capabilities, and target-market-specific requirements. Metecon makes these interdependencies transparent before any investment is made.
When is operational regulatory support no longer sufficient?
As soon as decisions have an impact across products or functions—such as in the areas of portfolio, market entry, growth, or reorganization—overarching strategic management is needed rather than individual measures.
Which risks arise when the regulatory impacts become apparent only later?
Delayed recognition of regulatory impacts leads to delays, rework, compromised sales and delivery capabilities, and costly course corrections. A strategy makes these consequences visible early on and manageable.
How does a regulatory strategy contribute to building regulatory resilience?
A strategy establishes priorities, responsibilities, and data structures in such a way that the company can manage changes and new requirements in a planned and organized manner. That is precisely what regulatory resilience is.
Which factors determine the effort and scope of a strategic consulting engagement?
The effort and scope depend on the product portfolio, target markets, the organization’s level of maturity, and the urgency of decision-making. Metecon typically starts with a focused workshop or gap analysis and scales up as needed.
Strategic Consulting: No-Obligation Initial Consultation
Whether it’s prioritization, market access, or portfolio decisions—we’ll work with you to identify a manageable path forward and, if you wish, implement it right away.
Your contact:
Dr. Caroline Arnold
Head of Sales
T: +49 621 123469-037
caroline.arnold@metecon.de
